Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Center, Korea
Janssen Research & Development, LLC
National Cancer Institute (NCI)
First Affiliated Hospital of Wenzhou Medical University
Hospital Centre Biel/Bienne
Fox Chase Cancer Center
University of Florida
Radiation Therapy Oncology Group
University of Bern
Mayo Clinic
UroGen Pharma Ltd.
Institute of Cancer Research, United Kingdom
UroGen Pharma Ltd.
European Organisation for Research and Treatment of Cancer - EORTC
Eli Lilly and Company